Cargando…
Improving naltrexone compliance and outcomes with putative pro- dopamine regulator KB220, compared to treatment as usual
A recent analysis from Stanford University suggested that without any changes in currently available treatment, prevention, and public health approaches, we should expect to have 510,000 deaths from prescription opioids and street heroin from 2016 to 2025 in the US. In a recent review, Mayo Clinic P...
Autores principales: | Blum, Kenneth, Lott, Lisa, Baron, David, Smith, David E, Badgaiyan, Rajendra D, Gold, Mark S |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7489288/ https://www.ncbi.nlm.nih.gov/pubmed/32934823 http://dx.doi.org/10.15761/JSIN.1000229 |
Ejemplares similares
-
Pro-Dopamine Regulator – (KB220) to Balance Brain Reward Circuitry in Reward Deficiency Syndrome (RDS)
por: Blum, Kenneth, et al.
Publicado: (2017) -
Pro-dopamine regulator, KB220Z, attenuates hoarding and shopping behavior in a female, diagnosed with SUD and ADHD
por: McLaughlin, Thomas, et al.
Publicado: (2018) -
Pro-Dopamine Regulator (KB220) A Fifty Year Sojourn to Combat Reward Deficiency Syndrome (RDS): Evidence Based Bibliography (Annotated)
por: Kenneth, Blum, et al.
Publicado: (2018) -
Opioid and dopamine genes interact to predict precision naltrexone response in alcohol use disorder: Interpretation misfires
por: Blum, Kenneth, et al.
Publicado: (2021) -
Enhanced functional connectivity and volume between cognitive and reward centers of naïve rodent brain produced by pro-dopaminergic agent KB220Z
por: Febo, Marcelo, et al.
Publicado: (2017)